Day: November 12, 2025

Chiesi Group Enters into an Exclusive License Agreement with Aliada Therapeutics, a Wholly Owned Subsidiary of AbbVie, to Advance Blood-Brain Barrier-Crossing Platform Technology in Lysosomal Storage Disorders

Evotec Receives Milestone Payment from Bristol Myers Squibb Following IND Acceptance in Strategic Protein Degradation Partnership

Milestone payment reflects continued progress under strategic research collaboration addressing high-need patient populationsFDA clearance of IND application triggered a US$...

error: Content is protected !!